Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report

• Published in: Respiratory medicine case reports Vol. 46; p. 101929
• Main Authors: Okada, Kohei, Sakakibara, Rie, Honda, Takayuki, Mitsumura, Takahiro, Shibata, Sho, Shirai, Tsuyoshi, Okamoto, Tsukasa, Furusawa, Haruhiko, Tateishi, Tomoya, Miyazaki, Yasunari
• Format: Report
• Language: English
• Published: 01.01.2023
• ISSN: 2213-0071; 2213-0071
• DOI: 10.1016/j.rmcr.2023.101929

A 74-year-old man was referred to our hospital with an abnormal chest shadow. Computed tomography (CT) revealed a mass in the left upper lobe and interstitial pneumonia (IP). The patient underwent CT-guided needle biopsy and was diagnosed as lung adenocarcinoma with cT2aN1M1a Stage IVA (PUL). The patient was administered 6 cycles of CBDCA + nab-paclitaxel as first-line, 3 cycles of atezolizumab as second-line, and 8 cycles of S-1 as third-line treatment but finally showed tumor progression. Because comprehensive genome profiling test revealed KRAS G12C mutation, sotorasib was initiated as fourth-line treatment and showed tumor regression without exacerbation of pre-existing IP.